Clinical decision aid for nirsevimab (Beyfortus™) in newborn infants

​ Download  
​
Decision aid to determine if a newborn infant is eligible to receive nirsevimab. Text alternative follows image.  

Text alternative

  1. Was maternal RSV vaccination (Abrysvo®) received at 28 to 36 weeks gestation1?
    1. If no, provide nirsevimab at birth3.
    2. If yes, was Abrysvo® received <2 weeks before delivery?
      1. I​f yes, provide nirsevimab at birth3.
      2. If no, was infant born with risk conditions for severe RSV disease2?
        1. If yes, provide nirsevimab at birth3.
        2. If no, was mother with severe immunosuppression2 or undergone cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO) (regardless of maternal vaccination status?
          1. If yes, provide nirsevimab at birth3.
          2. If no, nirsevimab not required.

Notes

  1. *Check maternal RSV vaccination status on the Australian Immunisation Register.
  2. ^Refer to NSW RSV Prevention Program - Eligibility for more information.
  3. #The dose of nirsevimab for infants weighing <5 kg, born during or entering their first RSV season, is 50 mg (0.5 mL). The dose of nirsevimab for infants weighing ≥5 kg, born during or entering their first RSV season, is 100 mg (1 mL). Nirsevi​mab is administered by intramuscular injection.
Current as at: Monday 20 January 2025
Contact page owner: Immunisation